This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
DHL Supply Chain, a contract logistics provider, is strengthening its life sciences and healthcare capabilities by agreeing to acquire SDS Rx, a provider of final-mile delivery and specialized healthcare transportation for long-term care and specialty pharmacies, radio pharmacies, and health system networks.
The acquisition will further expand DHL’s healthcare logistics portfolio, enhancing the company’s ability to deliver integrated, time-critical solutions across every stage of the life sciences and healthcare supply chain.
Processing specialized healthcare deliveries from more than 200 locations across the U.S., SDS Rx will add final-mile logistics services to DHL’s healthcare transportation network. The acquisition will also expand DHL’s same-day and expedited delivery capabilities for life sciences and healthcare customers.
“The life sciences and healthcare sector is projected to grow at a compound annual growth rate of 11% through 2030. Specialty pharmacy already accounts for approximately 50% of total prescription drug spending in the U.S., and the number of patients served by specialty pharmacies grew by 12% between 2018 and 2022. The increasing demand for specialty pharma and healthcare solutions presents significant opportunities for DHL to leverage its scale, expertise, and commitment to operational excellence. With this acquisition, we are expanding our healthcare logistics capabilities, attracting a new segment of healthcare customers, and reinforcing our position as a trusted partner in building resilient and connected healthcare supply chains,” says Mark Kunar, CEO of DHL Supply Chain North America.
Drew Kronick, Founder, CEO & Managing Partner of SDS Rx states, “Our mission is to enhance the quality of patient care with every delivery. As the demand for last mile delivery in healthcare continues to grow, we understand the importance of aligning with a partner who shares our patient-first commitment. Partnering with DHL represents a meaningful step forward, combining our strengths to improve the precision, reliability, and speed of delivery to patients most in need.”
This will be the second healthcare acquisition for DHL Supply Chain in 2025, following its purchase of CryoPDP, a specialty courier focused on clinical trials, biopharmaceuticals as well as cell and gene therapies, earlier this year. Together, these acquisitions will mark a milestone for DHL Group and its strategic growth agenda under Strategy 2030, particularly in expanding its logistics offerings in the Life Sciences and Healthcare sector. They strengthen DHL’s capabilities across critical areas of the healthcare supply chain—from pharmaceuticals and consumer health to animal health and medical technology—while paving the way for further targeted growth. With enhanced expertise in cold chain management and specialty pharma logistics, DHL will be even better positioned to meet the complex needs of the healthcare industry and support further targeted growth.
“At DHL, we take pride in our patient-centric approach to life sciences and healthcare solutions. As we continue to enhance our capabilities, our priority is to deliver efficient, seamless, and high-quality logistics services across every touchpoint of the healthcare supply chain. Strengthening healthcare final-mile delivery to serve health systems, care centers, and patients underscores our commitment to reliability and care,” says Jim Saponaro, President of Life Sciences and Healthcare for DHL Supply Chain North America.
DHL Supply Chain is committed to ensuring a seamless transition for customers and associates, with all employees becoming part of the DHL Supply Chain family. SDS Rx operations will be integrated into DHL Supply Chain North America’s Life Science & Healthcare business, and all teams will continue to operate under local leadership.
The closing of the acquisition is subject to regulatory approvals.
